United Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of “Buy” from Analysts

Shares of United Therapeutics Co. (NASDAQ:UTHRGet Rating) have been given a consensus rating of “Buy” by the nine ratings firms that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $208.40.

A number of equities research analysts have commented on the stock. StockNews.com raised shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 1st. Zacks Investment Research downgraded shares of United Therapeutics from a “buy” rating to a “hold” rating and set a $175.00 price objective on the stock. in a research report on Tuesday, March 1st. Wedbush reissued a “buy” rating and issued a $236.00 price objective (down from $276.00) on shares of United Therapeutics in a research report on Sunday, February 27th. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $230.00 to $223.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 19th. Finally, HC Wainwright reissued a “buy” rating on shares of United Therapeutics in a research report on Friday, February 25th.

In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction on Thursday, March 3rd. The shares were sold at an average price of $174.12, for a total value of $1,044,720.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders sold 36,000 shares of company stock valued at $6,801,060. Company insiders own 12.10% of the company’s stock.

A number of large investors have recently modified their holdings of the stock. Northwestern Mutual Investment Management Company LLC boosted its stake in United Therapeutics by 0.7% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 7,466 shares of the biotechnology company’s stock worth $1,613,000 after purchasing an additional 50 shares during the period. Advisor Partners LLC boosted its stake in United Therapeutics by 4.4% during the 4th quarter. Advisor Partners LLC now owns 1,249 shares of the biotechnology company’s stock worth $270,000 after purchasing an additional 53 shares during the period. CIBC Asset Management Inc boosted its stake in United Therapeutics by 3.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,871 shares of the biotechnology company’s stock worth $404,000 after purchasing an additional 55 shares during the period. Cardinal Capital Management boosted its stake in United Therapeutics by 0.9% during the 4th quarter. Cardinal Capital Management now owns 6,981 shares of the biotechnology company’s stock worth $1,508,000 after purchasing an additional 65 shares during the period. Finally, Daiwa Securities Group Inc. boosted its stake in United Therapeutics by 75.0% during the 3rd quarter. Daiwa Securities Group Inc. now owns 154 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 66 shares during the period. Hedge funds and other institutional investors own 96.46% of the company’s stock.

UTHR traded down $1.78 during trading hours on Friday, hitting $177.56. 236,715 shares of the company’s stock were exchanged, compared to its average volume of 377,440. United Therapeutics has a 12-month low of $158.38 and a 12-month high of $218.38. The firm has a 50 day moving average of $180.37 and a 200 day moving average of $192.73. The firm has a market cap of $8.01 billion, a P/E ratio of 17.70, a price-to-earnings-growth ratio of 6.81 and a beta of 0.67. The company has a current ratio of 7.61, a quick ratio of 7.30 and a debt-to-equity ratio of 0.20.

United Therapeutics (NASDAQ:UTHRGet Rating) last announced its earnings results on Thursday, February 24th. The biotechnology company reported $2.35 earnings per share for the quarter, missing the consensus estimate of $3.77 by ($1.42). United Therapeutics had a return on equity of 12.80% and a net margin of 28.23%. The business had revenue of $415.20 million for the quarter, compared to analysts’ expectations of $427.59 million. During the same period in the previous year, the company earned $2.19 earnings per share. United Therapeutics’s quarterly revenue was up 7.9% on a year-over-year basis. As a group, research analysts expect that United Therapeutics will post 14.07 EPS for the current fiscal year.

About United Therapeutics (Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Stories

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.